Clinical Trial Update: Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and reactogenicity of GSK's IPV vaccine Poliorix in toddlers completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• Poliorix (inactivated poliovirus vaccine (IPV))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Poliomyelitis | Phase 3 | Status: COMPLETED | Results posted: 2017-10-19